Gemin X Biotechnologies Inc. Initiates Phase 2 Clinical Trial Program For GX15-070 In Myelofibrosis And Hodgkin's Lymphoma
MONTREAL--(BUSINESS WIRE)--Sept. 14, 2006--Gemin X Biotechnologies Inc. announced today the initiation of a Phase 2 clinical trial program to evaluate GX15-070 in the treatment of several types of cancer. GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, thus restoring the natural cell death process of apoptosis.